| |
CR1 (N = 33)
|
CR > 1 (N = 75)
|
PR (N = 90)
|
Refractory (N = 38)
|
|---|
|
Outcomes
|
N
|
Prob (95% CI)
|
N
|
Prob (95% CI)
|
N
|
Prob (95% CI)
|
N
|
Prob (95% CI)
|
|---|
|
NRM
|
33
| |
75
| |
90
| |
38
| |
|
1-year
| |
6 (1–17)%
| |
20 (12–30)%
| |
20 (13–29)%
| |
24 (12–38)%
|
|
2-year
| |
13 (4–26)%
| |
29 (19–40)%
| |
25 (17–35)%
| |
30 (16–45)%
|
|
3-year
| |
17 (6–32)%
| |
31 (21–43)%
| |
25 (17–35)%
| |
30 (16–45)%
|
|
4-year
| |
17 (6–32)%
| |
36 (25–49)%
| |
33 (22–44)%
| |
30 (16–45)%
|
|
Progression/ relapse
|
33
| |
75
| |
90
| |
38
| |
|
1-year
| |
15 (5–29)%
| |
13 (7–22)%
| |
14 (7–21)%
| |
29 (16–44)%
|
|
2-year
| |
25 (12–41)%
| |
16 (9–26)%
| |
19 (11–28)%
| |
29 (16–44)%
|
|
3-year
| |
25 (12–41)%
| |
18 (10–28)%
| |
19 (11–28)%
| |
32 (18–48)%
|
|
4-year
| |
25 (12–41)%
| |
18 (10–28)%
| |
21 (12–30)%
| |
32 (18–48)%
|
|
PFS
|
33
| |
75
| |
90
| |
38
| |
|
1-year
| |
79 (63–91)%
| |
67 (56–77)%
| |
66 (56–76)%
| |
47 (32–63)%
|
|
2-year
| |
62 (45–78)%
| |
54 (43–66)%
| |
56 (45–66)%
| |
41 (26–57)%
|
|
3-year
| |
58 (41–75)%
| |
50 (38–62)%
| |
56 (45–66)%
| |
38 (23–54)%
|
|
4-year
| |
58 (41–75)%
| |
45 (33–58)%
| |
47 (36–58)%
| |
38 (23–54)%
|
|
Overall survival
|
33
| |
75
| |
90
| |
38
| |
|
1-year
| |
88 (75–97)%
| |
73 (63–83)%
| |
71 (61–80)%
| |
63 (47–78)%
|
|
2-year
| |
78 (62–90)%
| |
62 (51–73)%
| |
59 (48–69)%
| |
52 (36–67)%
|
|
3-year
| |
70 (52–85)%
| |
58 (46–70)%
| |
57 (47–68)%
| |
52 (36–67)%
|
|
4-year
| |
70 (52–85)%
| |
54 (41–66)%
| |
50 (39–62)%
| |
52 (36–67)%
|
- CR complete response, PR partial response, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival
